Company Filing History:
Years Active: 2014
Title: Ahmet Dogan: Innovator in T-Cell Lymphoma Research
Introduction
Ahmet Dogan is a notable inventor based in Rochester, MN, who has made significant contributions to the field of medical research, particularly in the area of T-cell lymphomas. His work focuses on the mechanisms involved in reducing the expression of specific polypeptides that play a crucial role in these types of cancers.
Latest Patents
Dogan holds a patent for "Reducing IRF4, DUSP22, or FLJ43663 polypeptide expression." This patent relates to the activity of interferon regulatory factor 4 (IRF4) in T-cell lymphomas. The document outlines methods and materials for reducing the expression of an IRF4 polypeptide in T-cell lymphoma cells. It also identifies agents capable of reducing the expression of DUSP22 or FLJ43663 polypeptides in T-cell lymphoma cells.
Career Highlights
Ahmet Dogan is affiliated with the Mayo Foundation for Medical Education and Research, where he conducts his research. His work has implications for developing new therapeutic strategies for treating T-cell lymphomas, which can significantly impact patient outcomes.
Collaborations
Dogan collaborates with esteemed colleagues such as Andrew L Feldman and George Vasmatzis, contributing to a rich environment of innovation and research in the field of oncology.
Conclusion
Ahmet Dogan's contributions to T-cell lymphoma research through his innovative patent highlight the importance of scientific inquiry in developing new treatment options. His work exemplifies the intersection of research and practical application in the medical field.